Tocilizumab Biosimilar (qyuns)

托珠单抗生物类似药 (qyuns)

Report date: 2025/02/28 20:00:34

Base Information

Drug NameTocilizumab Biosimilar (qyuns)

Drug Alias Name托珠单抗生物仿制药 (qyuns)QX-003-S

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists

TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

ATC CodeL04AC07